<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02046629</url>
  </required_header>
  <id_info>
    <org_study_id>PKM12788</org_study_id>
    <secondary_id>U1111-1152-4217</secondary_id>
    <nct_id>NCT02046629</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Pharmacokinetic Profiles of Single 14 mg Teriflunomide Tablet in Healthy Chinese Volunteers</brief_title>
  <official_title>An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Profiles of 14 mg Teriflunomide Tablet in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To assess the pharmacokinetic (PK) parameters of teriflunomide after a single oral dose of 14
      mg administration in Chinese healthy subjects

      Secondary Objective:

      To assess the safety and tolerability after a single oral dose of 14 mg teriflunomide in
      Chinese healthy subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Screening: 2 to 21 days before inclusion (Day -21 to Day -2)

        -  Institutionalization period: 6 days including 1 treatment day (Day -1 to Day 6,
           treatment on Day 1)

        -  Follow-up: 7-10 days (may be extended)

        -  End of study: Day 38 to Day 41 (may be extended)

        -  Total study duration: maximum 9 weeks
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters for teriflunomide determined from plasma concentration</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety assessments (adverse events, laboratory data, vital sign, and ECG parameters)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>teriflunomide dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teriflunomide 14mg tablet, oral single dose, fast condition Cholestyramine power, 8 gram,oral three times a day for 4 days, fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriflunomide HMR1726</intervention_name>
    <description>Pharmaceutical form:tablet Route of administration: oral</description>
    <arm_group_label>teriflunomide dose 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cholestyramine</intervention_name>
    <description>Pharmaceutical form:power Route of administration: oral</description>
    <arm_group_label>teriflunomide dose 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

        Male or female subjects, between 18 and 45 years of age, inclusive. Body weight between
        50.0 and 95.0 kg, inclusive, if male, and between 45.0 and 85.0 kg, inclusive, if female,
        body mass index between 19.0 and 24.0 kg/m2, inclusive.

        Certified as healthy by a comprehensive clinical assessment and lab test. Subject must use
        an appropriate contraception method. Having given written informed consent prior to any
        procedure related to the study.

        Exclusion criteria:

        Blood donation, any volume, within 3 months before inclusion. Symptomatic postural
        hypotension, whatever the decrease in blood pressure, or asymptomatic postural hypotension
        defined by a decrease in systolic blood pressure ≥20 mmHg within 3 minutes when changing
        from the supine to the standing position.

        Excessive consumption of beverages with xanthine bases (&gt;4 cups or glasses per day).

        If female, pregnancy (defined as positive β-hCG blood test), breast-feeding. Any medication
        (including St John's Wort and traditional Chinese herb medicine) within 14 days before the
        inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of that
        drug, with the exception of hormonal contraception or menopausal hormone replacement
        therapy; any vaccination within the last 28 days.

        Any consumption of citrus (grapefruit, orange, etc) or their juices within 5 days before
        inclusion.

        Subject (both male and female) who disagrees to use an appropriate contraception method .

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 156001</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <last_update_submitted>August 20, 2014</last_update_submitted>
  <last_update_submitted_qc>August 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestyramine Resin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

